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After a drug goes to market
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Context: medication-assisted 
treatment for opioid dependence
 Methadone maintenance (an opioid agonist)
 Naloxone (an opioid antagonist)
 Buprenorphine/naloxone (Suboxone®)
 Introduced in 2003
 Safer than methadone
 Can be dispensed in an outpatient setting and 
taken without direct observation
 It reaches a new group of patients with 
addiction
Buprenorphine/naloxone 
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Variation isn’t explained by need
Opioid addiction prevalence Suboxone ® Use
The media weighs in
“Suboxone is gaining traction as the safest and 
most effective treatment for opioid addiction.”
“One might think that state public health 
officials would vigorously embrace the newer 
drug. They don't. Or that doctors, especially 
psychiatrists, would be lining up to learn more 
about the drug. They aren't.”
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Problem: Access is limited
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Problem: Access is limited
Response: Expanded number
of patients per provider
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Response: prescriber 
demand not met
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Problem: 
Concerns about
diversion
Response: Restrictions
on access
Myth or Evidence?
• The Globe: Suboxone is more effective
• The Evidence: favors methadone
Effectiveness evidence favors methadone
• We studied 33,923 MassHealth members with 
opioid addiction between 2003 and 2007
• 53,557 treatment episodes
• Used an intent to treat model with patient 
matching to compare effectiveness
• Significantly more use of relapse-related 
services in the Suboxone group
• Clinical trials agree
Myth or Evidence?
• The Globe: All patients should use Suboxone®
• The evidence:
• Methadone works better for some patients
• Suboxone® patients had more behavioral 
health disorders, fewer physical problems 
than methadone users
• Other studies show differences in 
employment, age and other characteristics
Myth or Evidence?
• The Globe: Massachusetts has been slow to 
adopt Suboxone® 
• The Evidence: Only 2 states use Suboxone® 
more intensively than Massachusetts
Myth or Evidence?
• The Globe says Suboxone patients cost about 
$666 less per month than methadone
• MassHealth says Suboxone is too expensive.
• The Evidence: our analysis shows that 
Suboxone costs about $29 less per month 
than methadone
Myth or Evidence?
• The Globe: Did not mention the large numbers 
of patients not using any medication-assisted 
treatment
• The Evidence: Death rates are significantly 
lower among MAT users than drug-free users
• There is no difference in death rates between 
methadone and buprenorphine users
Myth or Evidence?
• The Globe: not enough providers are trained 
to prescribe Suboxone.
• The Evidence: the percentage of trained 
prescribers is higher in Massachusetts than in 
most other states.
• There are still not enough providers to meet 
demand.
How do we improve?
• Invest in independent comparative evaluation 
of medications
• Focus on value not just cost
• Measure total cost rather than drug cost
• Acknowledge patient differences
• Incentivize prescriber certification 
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